Literature DB >> 24638130

Multiple sclerosis: Atacicept increases relapse rates in multiple sclerosis.

Ellen Bible.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24638130     DOI： 10.1038/nrneurol.2014.48

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  1 in total

1.  Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

Authors:  Ludwig Kappos; Hans-Peter Hartung; Mark S Freedman; Alexey Boyko; Ernst Wilhelm Radü; Daniel D Mikol; Marc Lamarine; Yann Hyvert; Ulrich Freudensprung; Thomas Plitz; Johan van Beek
Journal:  Lancet Neurol       Date:  2014-03-06       Impact factor: 44.182
  1 in total
  2 in total

Review 1.  Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases-Implications for Therapeutic Approaches.

Authors:  Tanja Fetter; Dennis Niebel; Christine Braegelmann; Joerg Wenzel
Journal:  Cells       Date:  2020-12-07       Impact factor: 6.600

Review 2.  Role of CXCL13 in the formation of the meningeal tertiary lymphoid organ in multiple sclerosis.

Authors:  Ana C Londoño; Carlos A Mora
Journal:  F1000Res       Date:  2018-04-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.